A comparison of how the investigational drug retatrutide stacks up on weight loss against existing obesity treatments.
Recap by typeshit. Full story at BusinessWorld Online.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
BusinessWorld reports on a newer class of weight loss drugs that it says is beating Ozempic on results.
Penn State Science says the new funding supports work that uses AI to identify synthetic peptides with potential for drug development.
Loading…